In recent years, it has become necessary to take multiple approaches to comprehensively address a question or test a hypothesis in biomedical research. For labs that do not have biochemical expertise, the Biochemical Pharmacology Core offers help that facilitates their research. In the past nine years, the Core has offered short- and long-term assistance to mainly chemists and behavioral scientists in doing receptor binding, immunoblotting and Signaling following receptor activation. The work has resulted in many publications and provided preliminary results for several grant applications.
The specific aims of this application are for the Core to prove the following services: (1) Receptor binding: opioid. dopamine and nicotinic receptors and others when necessary;(2) Receptor autoradiography: opioid receptors and others when required;(3) Assessment of receptor activation by determination of cAMP level. [35S]GTPgS binding, and p44/42 MAP kinase phosphorylation;(4) Protein gel electrophoresis and immunoblotting;(5) Assessment of suitability of receptor antibodies for immunoblotting: opioid receptors initially and others when needed. The services that the Core will provide are valuable to researchers in the drug abuse field, both within and outside of Temple University. The latter group includes Drs. David Y.-W. Lee, Bruce Cohen and Cecile Beguin of Harvard Medical School, Dr. Julie Blendy, University of Pennsylvania, Dr. Michelle Ehrlich of Mt. Sinai School of Medicine. Dr. Sari Izenwasser of University of Miami. Since Dr. Liu-Chen's lab has a great deal of experience in these techniques, the data are of high quality. Dr Liu-Chen's lab has generated and purified MOPR antibodies and has worked out conditions that the antibodies worked well for immunoblotting. A new addition in this renewal is that the Core will perform immunoblotting of endogenous MOPR and/or will provide purified MOPR antibodies for researchers. Moreover, the Core will evaluate antibodies against other molecules of interest in the drug abuse area (opioid receptors and possibly others) for immunoblotting. If so, these antibodies will be valuable tools for researchers in the field. Thus, the Core is a valuable resource for researchers in the drug abuse field whose expertise is outside of biochemical area.

Public Health Relevance

The core provides biochemical pharmacology services to scientists in the drug abuse field whose expertise is non-biochemical in nature. The services will facilitate the progress of many research programs and advance our knowledge of the mechanisms underlying drug abuse and addiction.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
United States
Zip Code
Console-Bram, Linda; Brailoiu, Eugen; Brailoiu, Gabriela Cristina et al. (2014) Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol 171:3908-17
Miller, Jonathan S; Barr, Jeffrey L; Harper, Lauren J et al. (2014) The GSK3 signaling pathway is activated by cocaine and is critical for cocaine conditioned reward in mice. PLoS One 9:e88026
Zhao, Pingwei; Lane, Tom R; Gao, Helen G L et al. (2014) Crucial positively charged residues for ligand activation of the GPR35 receptor. J Biol Chem 289:3625-38
Chatila, W M; Criner, G J; Hancock, W W et al. (2014) Blunted expression of miR-199a-5p in regulatory T cells of patients with chronic obstructive pulmonary disease compared to unaffected smokers. Clin Exp Immunol 177:341-52
Enman, Nicole M; Zhang, Yong; Unterwald, Ellen M (2014) Connecting the pathology of posttraumatic stress and substance use disorders: monoamines and neuropeptides. Pharmacol Biochem Behav 117:61-9
Shi, Xiangdang; Miller, Jonathan S; Harper, Lauren J et al. (2014) Reactivation of cocaine reward memory engages the Akt/GSK3/mTOR signaling pathway and can be disrupted by GSK3 inhibition. Psychopharmacology (Berl) 231:3109-18
Kong, Weimin; Li, Hongbo; Tuma, Ronald F et al. (2014) Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS. Cell Immunol 287:1-17
Dimattio, K M; Yakovleva, T V; Aldrich, J V et al. (2014) Zyklophin, a short-acting kappa opioid antagonist, induces scratching in mice. Neurosci Lett 563:155-9
Lucchesi, Valentina; Hurst, Dow P; Shore, Derek M et al. (2014) CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides. J Med Chem 57:8777-91
Cathel, Alessandra M; Reyes, Beverly A S; Wang, Qin et al. (2014) Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex. Eur J Neurosci 40:3202-14

Showing the most recent 10 out of 195 publications